Castle BiosciencesCSTL
Recorded

Castle Biosciences 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration40 minParticipants13

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon and welcome to Castle Biosciences Third Quarter 2026 Conference Call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question-and-answer session. I would now like to turn the call over to Camilla Zucchero, Vice President Investor Relations and Corporate Affairs. Thank you. You may begin.

Camilla ZuckeroVP of Investor Relations and Corporate Affairs

Thank you, operator. Good afternoon, everyone. Welcome to Castle Biosciences Third Quarter 2026 Results Conference Call. Joining me today are Castle's founder, President, and Chief Executive Officer, Derek Maetzold, and Chief Financial Officer, Frank Stokes. Information recorded on this call speaks only as of today, November 5, 2026. Therefore, if you are listening to the replay or reading the transcript of this call, any time-sensitive information may no longer be accurate. A recording of today's call will be available on the Investor Relations page of the company's website for approximately three weeks following the conclusion of the call.

Camilla ZuckeroVP of Investor Relations and Corporate Affairs

Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements, including statements about expected addressable markets, statements containing projections regarding future events or our future financial or operational results and performance, including our anticipated 2026 total revenue, test report volume growth guidance, and positive Adjusted EBITDA for the fourth quarter, full year 2026, and full year 2027, and the impact of our investments and growth initiatives, including our ability to achieve long-term growth and drive stockholder value. Forward-looking statements are based upon current expectations and involve inherent risks and uncertainties, and there can be no assurances that the results contemplated in these statements will be realized. A number of factors and risks could cause actual results to differ materially from those contained in these forward-looking statements.

Camilla ZuckeroVP of Investor Relations and Corporate Affairs

Please refer to the risk factors in our most recent SEC filings for more information. These forward-looking statements speak only as of today, and we assume no obligation to update or revise these forward-looking statements as circumstances change. In addition, some of the information discussed today includes non-GAAP financial measures such as adjusted revenue, adjusted gross margin, and Adjusted EBITDA that have not been calculated in accordance with U.S. GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today, which has been posted on the Investor Relations page of the company's website. I will now turn the call over to Derek.

Derek MaetzoldFounder, President, and CEO

Thank you, Camilla, and good afternoon, everyone. Our team closed out a very successful third quarter, reflecting our focused execution and disciplined expense management, underscored by the clinical value our tests provide to clinicians and their patients. We delivered revenue of $102.9 million, 24% growth compared to the third quarter of 2025, primarily driven by TissueCypher test report volume, which grew by 47% compared to the third quarter of 2025. We generated $19.7 million in net cash provided by operating activities and end of the quarter with cash equivalents, and marketable investment securities totaling approximately $278 million. We are increasing our full year 2026 total revenue guidance from our prior range of $365 million to $375 million to $385 million-$395 million.

Derek MaetzoldFounder, President, and CEO

This represents a $20 million increase at the midpoint, reflecting our year-to-date performance and anticipated continued strength in TissueCypher test volume growth. Importantly, at the midpoint, our updated guidance represents a $45 million increase from where we entered the year. Now, I will walk you through the business highlights from the third quarter, and then Frank will provide additional financial highlights before we turn to your questions. First, let me take a moment to thank the Castle team. Without each person's dedication to serving our patients, we would not be in the strong financial position we are in today. So thank you, Team Castle. Now, let's start with our core revenue drivers for 2026, DecisionDx-Melanoma and TissueCypher.

Derek MaetzoldFounder, President, and CEO

For DecisionDx-Melanoma, we delivered 10,177 test reports in the third quarter of 2026, making our fifth consecutive quarter exceeding 10,000 test reports and contributing to 5% year-over-year volume growth through the first nine months of 2026 compared to the first nine months of 2025. DecisionDx-Melanoma remains a central priority for our dermatology commercial organization. We've aligned commercial focus and incentive structures to reinforce that priority while leveraging our established customer relationships to increase use of our broader portfolio of dermatology tests. Our objective is to drive continued adoption of DecisionDx-Melanoma while building future growth opportunities across our dermatology tests. With DecisionDx-Melanoma continuing to provide a durable foundation for our dermatology business and reflecting third quarter and year-to-date test report volume, we are refining our outlook for full year 2026 DecisionDx-Melanoma test volume growth and now expect mid-single-digit year-over-year growth compared with 2025. Now, turning to TissueCypher. During the third quarter, we delivered 15,574 test reports, representing strong growth of 47% compared to the third quarter of 2025.

Derek MaetzoldFounder, President, and CEO

This performance reflects continuing momentum in our commercial execution, driven by increased utilization among our existing clinician base and, to a lesser degree, the addition of new ordering clinicians. Based on our year-to-date performance, we are reiterating our expectation for full year 2026 TissueCypher test report volume growth of 50%-52% compared to 2025. Alongside this strong commercial performance, we remain focused on expanding the body of clinical evidence supporting TissueCypher's utility in helping physicians make more informed, risk-aligned management decisions for patients with Barrett's esophagus disease. In September, we announced the publication of a new decision modeling study in the Annals of Gastroenterology.

Derek MaetzoldFounder, President, and CEO

This study, which leveraged data from 699 patients across five previously published clinical validation studies, demonstrated that incorporating TissueCypher results into clinical decision-making could significantly improve the portion of patients receiving appropriate management, including in patients with non-dysplastic and short-segment Barrett's, who are considered clinically to be at lower risk for neoplastic progression. In patients with non-dysplastic Barrett's disease, whose disease did progress, use of TissueCypher to guide management decisions increased appropriate management in the form of endoscopic eradication therapy or short-interval surveillance from 30.4% to 56.9%. Notably, among patients with non-dysplastic Barrett's who later progressed to high-grade dysplasia or esophageal cancer, TissueCypher-guided management would have nearly doubled the proportion of patients receiving appropriate escalation of care from approximately 30% to 57%, while also reducing unnecessary procedures among those patients who did not progress.

Derek MaetzoldFounder, President, and CEO

We believe these findings add to the growing body of evidence supporting TissueCypher's clinical value and further reinforce its role in helping physicians tailor patient management based on individualized risk of disease progression. Now, let's move back to dermatology and focus on our AdvanceAD-Tx tests. During the third quarter of 2026, we delivered 1,109 test reports, reinforcing the value of our AdvanceAD-Tx tests. We were particularly pleased with the recent publication of a new study in Dermatology and Therapy highlighting, one, the challenges patients with moderate to severe atopic dermatitis experience in achieving their treatment goals, and two, strong patient interest in molecular testing to help guide systemic therapy selection. Among patients who had been treated with targeted systemic therapies, 55% modified their treatment due to lack of efficacy.

Derek MaetzoldFounder, President, and CEO

Overall, 83% of respondents expressed interest in molecular testing to guide treatment selection, increasing to 94% among those open to initiating a new systemic therapy. Further, in a real-world clinical use study that was presented in June at the Revolutionizing Atopic Dermatitis, or RAD, Conference, found 98% of patients tested had their systemic treatment aligned with our AdvanceAD-Tx test results, meaning the 94% interest in patients new to systemic therapy who were interested in molecular testing aligns well with the 98% that Dr. Ames and colleagues reported at the RAD Conference. We believe these findings support the clinical impact that our test is having on patient care. With that, I will now turn the call over to Frank.

Frank StokesCFO

Thank you, Derek. Good afternoon. Reiterating Derek's sentiment, we're pleased with our strong financial results for the third quarter of 2026. Revenue was $102.9 million for the quarter, an increase of 24% over the third quarter of 2025, driven primarily by strong TissueCypher test volume growth. For total revenue for 2026, we are raising our revenue guidance to $385 million-$395 million, up from the previously provided range of $365 million-$375 million. This increase is primarily due to anticipated TissueCypher test volume growth and, to a lesser extent, ASP improvement. Our gross margin during the third quarter of 2026 was 75%, compared to 75% in the third quarter of 2025.

Frank StokesCFO

Our adjusted gross margin, which excludes the effects of intangible asset amortization related to our acquisitions and excludes the effects of revenue adjustments in the current period associated with test reports delivered in prior periods, was 77% for the quarter, compared to 77% for the same period in 2025. Turning to expenses, our total operating expenses, including cost of sales for the third quarter of 2026, were $105.6 million, compared to $89.8 million for the third quarter of 2025. Sales and marketing expenses for the quarter were $37.7 million, compared to $32.8 million for the same period in 2025, primarily driven by higher personnel costs and higher expenses associated with travel. Higher personnel costs reflect headcount additions in our commercial teams, as well as merit and annual inflationary wage adjustment for existing employees.

Frank StokesCFO

General and administrative expenses were $26.1 million for the quarter, compared to $23.1 million for the same period in 2025, primarily attributable to higher information technology-related costs and higher personnel costs. Higher personnel costs reflect headcount expansions in our administrative functions, as well as merit and annual inflationary wage adjustment for existing employees. Cost of sales expenses were $23.9 million in the third quarter of 2026, compared to $18.7 million in the third quarter of 2025, primarily due to higher personnel costs, higher expenses for lab supplies, and higher lab services costs. The increase in lab supplies and lab services costs reflect higher test report volumes. Increases in personnel costs reflect a higher headcount due to higher test volumes, investment additions made to support planned business growth in response to growing test report volumes, as well as merit and annual inflationary wage adjustment for existing employees.

Frank StokesCFO

R&D expenses were $15.8 million for the quarter, compared to $13 million for the same period in 2025, primarily due to higher personnel costs driven by increased headcount to support ongoing research activities and continued business growth related to our pipeline initiatives. Total non-cash stock-based compensation expense, which is allocated among cost of sales, R&D, and SG&A expense, was $11.2 million for the third quarter of 2026, compared to $12.1 million in the third quarter of 2025. Interest income was $2.5 million for the third quarter of 2026, compared to $2.8 million in the third quarter of 2025. Our net loss for the third quarter of 2026 was $4.1 million, compared to a net loss of $0.5 million for the third quarter of 2025.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day